CAR T 세포 치료 시장 : 적응증별, 최종 용도별 - 세계 예측(2024-2030년)

[195 Pages Report] The CAR T-cell Therapy Market size was estimated at USD 5.08 billion in 2023 and expected to reach USD 5.35 billion in 2024, at a CAGR 5.00% to reach USD 7.15 billion by 2030.

Global CAR T-cell Therapy Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the CAR T-cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the CAR T-cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the CAR T-cell Therapy Market, highlighting leading vendors and their innovative profiles. These include AbClon Inc., Abintus Bio, Inc., AffyImmune Therapeutics Inc., Aleta Biotherapeutics, Amgen Inc., Anixa Biosciences, Inc., Aurora BioPharma, Inc., Autolus Therapeutics PLC, Bellicum Pharmaceuticals, Inc., BioNTech SE, Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited by Huadong Medicine Co., Ltd., Cellectis SA, Celyad Oncology SA, Fate Therapeutics, Inc., Gilead Sciences, Inc., Intellia Therapeutics, Inc., Janssen Global Services, LLC by Johnson & Johnson Services, Inc., Legend Biotech Corporation by Genscript Biotech Corporation, Les Laboratories Servier, Mustang Bio by Fortress Biotech, Inc., Noile-immune Biotech, Inc., Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the CAR T-cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Indication
  • Hematologic Malignancies
    • Leukemia
    • Lymphoma
    • Myeloma
  • Solid Tumors
    • Brain & Central Nervous System
    • Liver Cancer
    • Melanoma
• End-Use
  • Cancer Treatment Centers
  • Hospitals
• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the CAR T-cell Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the CAR T-cell Therapy Market?

3. What are the technology trends and regulatory frameworks in the CAR T-cell Therapy Market?

4. What is the market share of the leading vendors in the CAR T-cell Therapy Market?

5. Which modes and strategic moves are suitable for entering the CAR T-cell Therapy Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. CAR T-cell Therapy Market, by Region

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in the prevalence of multiple myeloma cancer, lymphoma and leukemia
    • 5.1.1.2. Availability of adequate reimbursements for CAR T-cell therapy with government awareness
    • 5.1.1.3. Increasing adoption of gene and cell therapy
  • 5.1.2. Restraints
    • 5.1.2.1. Limitations of the efficacy of CAR T-cell immunotherapy
  • 5.1.3. Opportunities
    • 5.1.3.1. Exponential R&D funding and partnership for indigenous CAR-T therapy
    • 5.1.3.2. Government support and initiative for the adoption of CAR T-cell immunotherapy
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with safety and possible side effects
• 5.2. Market Segmentation Analysis
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework

6. CAR T-cell Therapy Market, by Indication

• 6.1. Introduction
• 6.2. Hematologic Malignancies
  • 6.3.1. Leukemia
  • 6.3.2. Lymphoma
  • 6.3.3. Myeloma
• 6.3. Solid Tumors
  • 6.4.1. Brain & Central Nervous System
  • 6.4.2. Liver Cancer
  • 6.4.3. Melanoma

7. CAR T-cell Therapy Market, by End-Use

• 7.1. Introduction
• 7.2. Cancer Treatment Centers
• 7.3. Hospitals

8. Americas CAR T-cell Therapy Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific CAR T-cell Therapy Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa CAR T-cell Therapy Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

• 12.1. Key Company Profiles
  • 12.1.1. AbClon Inc.
  • 12.1.2. Abintus Bio, Inc.
  • 12.1.3. AffyImmune Therapeutics Inc.
  • 12.1.4. Aleta Biotherapeutics
  • 12.1.5. Amgen Inc.
  • 12.1.6. Anixa Biosciences, Inc.
  • 12.1.7. Aurora BioPharma, Inc.
  • 12.1.8. Autolus Therapeutics PLC
  • 12.1.9. Bellicum Pharmaceuticals, Inc.
  • 12.1.10. BioNTech SE
  • 12.1.11. Bristol-Myers Squibb Company
  • 12.1.12. CARsgen Therapeutics Holdings Limited by Huadong Medicine Co., Ltd.
  • 12.1.13. Cellectis SA
  • 12.1.14. Celyad Oncology SA
  • 12.1.15. Fate Therapeutics, Inc.
  • 12.1.16. Gilead Sciences, Inc.
  • 12.1.17. Intellia Therapeutics, Inc.
  • 12.1.18. Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
  • 12.1.19. Legend Biotech Corporation by Genscript Biotech Corporation
  • 12.1.20. Les Laboratories Servier
  • 12.1.21. Mustang Bio by Fortress Biotech, Inc.
  • 12.1.22. Noile-immune Biotech, Inc.
  • 12.1.23. Novartis AG
  • 12.1.24. Pfizer Inc.
  • 12.1.25. Sorrento Therapeutics, Inc.
• 12.2. Key Product Portfolio

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing